The company said, “Revenue for the full year 2025 is expected to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL:
- CVS Health upgraded, Occidental downgraded: Wall Street’s top analyst calls
- Carlsmed initiated with a Buy at Truist
- Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation
- Carlsmed initiated with a Buy at BofA
- Carlsmed initiated with a Buy at BTIG